Fluorescent Viral Surrogate Nanoparticles for Clearance Validation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for viral clearance validation in biologic drug manufacturing, such as live virus spiking studies, are costly, time-consuming, and require Biosafety Level 2 environments, limiting their feasibility in industrial settings and lacking sensitivity in quantifying viral surrogates.
Innovation Solution
Development of viral surrogate nanoparticles with a core and a surface-mimicking layer that mimic the size, shape, and charge of target live viruses, allowing for their use in viral clearance evaluation processes within a BSL-1 environment, using a membrane separator and fluorescence quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live virus spiking studies are performed to evaluate viral clearance, then the evaluation is representative of actual viral behavior, but the process becomes costly, time-consuming, and requires BSL-2 environments
Solution Approach 1:
The patent creates viral surrogate nanoparticles that copy the essential physical and chemical properties of live viruses (size, shape, surface charge, hydrophobicity) without requiring live viral material. These surrogates are used in viral clearance studies instead of actual viruses, maintaining representativeness while eliminating the need for BSL-2 facilities and reducing costs
Solution Approach 2:
The patent introduces viral surrogate nanoparticles as an intermediary substance that mediates between the need for realistic viral behavior in studies and the practical constraints of cost, time, and safety. These surrogates serve as a substitute that allows studies to be performed in simpler BSL-1 environments
2Reliability
If live virus spiking studies are performed, then viral clearance can be validated, but the process takes months to complete and costs hundreds of thousands of dollars
Solution Approach 1:
By using viral surrogate nanoparticles that replicate viral properties, the patent eliminates the need for lengthy live virus culture and propagation steps, reducing the validation process from months to a much shorter timeframe while maintaining clearance validation reliability
Solution Approach 2:
The viral surrogate nanoparticles are pre-characterized and ready for use, eliminating the need for time-consuming live virus preparation, culture, and propagation steps that traditionally precede clearance studies
3Ease of manufacture
If conventional quantification methods are used for viral surrogates, then the process is simpler, but the sensitivity range is narrow and not representative of live virus quantification
Solution Approach 1:
The patent incorporates fluorescent materials into the viral surrogate nanoparticles, enabling detection through fluorescence spectroscopy. This approach provides a wide dynamic range of sensitivity that mirrors live virus quantification methods while maintaining operational simplicity
4Reliability
If viral surrogates are developed to mimic live viruses, then the representativeness improves, but the complexity of surrogate design and fabrication increases
Solution Approach 1:
The patent focuses on replicating only the essential local properties of viruses that are critical for clearance study representativeness (surface charge, hydrophobicity, size, shape) rather than attempting to recreate the entire viral structure, including non-essential internal components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables efficient and sensitive viral clearance validation in a BSL-1 setting, reducing costs and time, while providing a more representative mimicry of live viruses for improved process evaluation.
Implementation Method 1
The particles include a core including one or more fluorescent materials
Implementation Method 2
the surfaces being configured to bind the viral surface-mimicking layer of the viral surrogate nanoparticles
Data Source
AI summary
Evaluating viral clearance of a sample including a drug of interest is performed via modified viral surrogate nanoparticles that mimic a target live virus equivalent. The nanoparticles include fluorescent materials and a viral surface-mimicking layer that physicochemically mimics the external surface of the target live virus equivalent. One or more capsid proteins of the live virus are bound to the nanoparticle core (for non-enveloped viruses) or incorporated into a lipid bilayer (for enveloped viruses). A process solution is formed by adding the nanoparticles to the sample. The solution is subjected to purification steps to eliminate impurities, forming a product process solution. The product process solution is filtered through a dead-end flow nanofiltration membrane separator configured to bind the fluorescent nanoparticles. A load process solution is filtered as well. Baseline decomposition of the fluorescence intensity measurements from the separate membranes can, upon application of a standard curve indicate the relative nanoparticle concentration and thus the efficacy of the purification steps against the target live virus equivalent.